CVRx® Granted CE Marking of the Barostim neo System™ for Conditional MRI Compatibility

Minneapolis – December 11, 2014 – CVRx, Inc., a privately held medical device company, announced today that CE Marking has been granted to expand labeling of the Barostim neo System™ as MR Conditional, or safe for use in Magnetic Resonance Imaging (MRI) systems under specified conditions. By enabling access to MRI scans, the expanded labeling will benefit patients receiving Barostim Therapy for heart failure or resistant hypertension.

 

“This approval has the potential to benefit many patients and their health care providers as MRI is critical in the diagnosis of serious conditions which can occur in the populations served by Barostim Therapy. We are pleased to enable access to this diagnostic option for our current and future patients,” said Nadim Yared, CEO of CVRx.

 

About Barostim Therapy™

CVRx has completed 6 month follow-up in a 146 patient randomized, controlled clinical trial to demonstrate the performance of Barostim Therapy in patients suffering from chronic heart failure with advanced symptoms. Promising results from an earlier study demonstrating clinical improvement and reduced hospitalizations have been presented and published.1 The six month results from the randomized, controlled trial are being prepared for publication.

 

Five-year results of the 322-patient sham-controlled Rheos Hypertension Trial were presented at the American Society of Hypertension and the joint European and International Societies of Hypertension annual scientific conferences in May and June of 2014. The results showed a persistent and statistically significant reduction of systolic and diastolic blood pressure in excess of 32mmHg and 17mmHg, respectively, over the course of 5 years. In addition, the long term safety profile of the therapy proved to be excellent with very low rates of stroke, myocardial infarction and worsening of carotid stenosis in this population of patients with advanced hypertension.2,3

 

Barostim Therapy is included in the joint European Society of Hypertension and European Society of Cardiology guidelines for the treatment of resistant hypertension that were published in June, 2013.4

 

About Barostim neo

Barostim neois a second generation device that uses CVRx-patented technology that is designed to trigger the body’s own natural blood flow regulation system to treat patients suffering from chronic heart failure and resistant hypertension. The system works by electrically activating the baroreceptors, the body’s natural sensors that regulate cardiovascular function. By activating this afferent pathway, Barostim restores sympatho-vagal balance by reducing sympathetic activity and increasing parasympathetic activity.

 

Key unique benefits:

  • The Barostim neo can be turned on and off to demonstrate acute results;
  • It can be adjusted to meet each patient’s individual therapy needs;
  • It is a reversible treatment;
  • It provides 100 percent compliance to treatment by continuously activating the baroreflex;
  • It is compatible with and complementary to implantable cardio-defibrillators and cardiac resynchronization therapy5; and
  • It is now MR Conditional, or safe for use under specified conditions

 

About Heart Failure

In heart failure, heart function is impaired, resulting in shortness of breath, exercise intolerance and fluid retention. In the United States, heart failure is estimated to affect 5.1 million adults.6 Overall, heart failure is associated with a four-fold increased risk of death and a six to nine times increased risk of sudden cardiac death. The direct and indirect costs of heart failure are estimated to be $32 billion in the United States in 2013.6

 

About Hypertension

In Europe, the prevalence of hypertension is estimated to be between 30-45% of the general population.4 In the United States, hypertension affects 77.9 million people.8 Worldwide, hypertension is estimated to cause one in every eight deaths.7 It is a major risk factor for cardiovascular disease, morbidity and mortality. Twenty-five percent of people with hypertension cannot adequately control their hypertension with medications and lifestyle modifications.7,8 It is a disease that needs new treatment solutions.

 

About CVRx, Inc.

CVRx, Inc. is a privately held company founded in 2001 and headquartered in Minneapolis. The company has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension (high blood pressure). Barostim neohas received CE Marking for the treatment of heart failure in addition to CE Marking for hypertension in Europe. It is under clinical evaluation for the treatment of heart failure and hypertension in the United States.

 

CVRx Contacts:

John BrintnallChief Financial Officerjbrintnall@cvrx.com

Phone: 763.416.2853

Tom MooreVice President of Sales Operations, Marketingand Field Clinical Support

tmoore@cvrx.com

Phone: 763.258.9039

 

Footnotes:

  1. Gronda E, et al. Chronic baroreflex activation effects on sympathetic nerve traffic, baroreflex function and cardiac haemodynamics in heart failure: a proof of concept study.   European Journal of Heart Failure 2014; 16(9):977-983
  2. Bakris G, et al. Baroreflex activation therapy reduces blood pressure for at least five years in a large resistant hypertension cohort. J Am Soc Hypertens. 2014; 8(4S) e9-e10
  3. de Leeuw P, et al. Validation of long-term blood pressure control with baroreflex activation therapy in a large cohort of resistant hypertension patients. Journal of Hypertension. 2014; Vol 32, Suppl. 1; 27
  4. Mancia G, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal 2013 34 (28): 2159-2219
  5. Madershahian N, et al. Baroreflex activation therapy in patients with preexisting implantable cardioverter-defibrilator: Compatible, complementary therapies. Europace Feb, 2014
  6. Go A, Heart Disease and Stroke Statistics. American Heart Association – 2013 Update. Circulation 2013;127:e6-e245
  7. Prospective Studies Collaboration. Lancet 2002;360:1903-1913
  8. Chobanian AV. JNC 7: Complete Report. JAMA 2003;289:2560-2572

 

CAUTION: Barostim neo™ is an investigational device and is limited by United States law to investigational use. Exclusively for Clinical Investigations for the treatment of heartfailure and resistant hypertension in Canada.

CVRx, HOPE4HF, Barostim neo and Barostim Therapyare trademarks of CVRx, Inc. registered in the United States Trademark Office.

© CVRx, Inc. 2014. All rights reserved.